Amgen Said to Push for Lower Onyx Price Amid Data Dispute

Amgen Inc. is pushing to pay less than the $130 a share it offered this month for Onyx Pharmaceuticals Inc. after failing to obtain requested clinical trial data, said people with knowledge of the matter.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.